Tris Pharma Presents Data Reinforcing Limited Abuse Potential of Investigational Pain Therapy Cebranopadol at the 2023 PAINWeek Conference
MONMOUTH JUNCTION, N.J.--(BUSINESS WIRE)--Tris Pharma, Inc. (Tris), a commercial-stage biopharmaceutical company focused on ADHD, pain and neurological disorders, today announced that the company has been awarded a grant expected to provide up to $16.6M over five years from the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health (NIH). Through the Helping to End Addiction Long-term® Initiative (NIH HEAL Initiative®), NIH has awarded grants to fund the optimization of new therapies to prevent and treat opioid use disorder (OUD).
MONMOUTH JUNCTION, N.J., Dec. 13, 2022 /PRNewswire/ -- Tris Pharma, Inc. (Tris), a fully integrated, innovation-driven pharmaceutical company focused on CNS disorders, today announced new clinical data from its oral human abuse potential study in patients who are nondependent recreational opioid users, which demonstrate that cebranopadol (TRN-228) possesses significantly less likeability at high doses, above the therapeutic range versus immediate release (IR) formulations of tramadol or oxycodone. These data suggest that cebranopadol has a lower potential for abuse versus both C-II and C-IV opioids.